Evaluation of the Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel Mixed With Mitomycin C (MMC) in Non-muscle Invasive Bladder Cancer (NMIBC) Patients
Phase of Trial: Phase II
Latest Information Update: 21 Jun 2017
At a glance
- Drugs Mitomycin (Primary)
- Indications Bladder cancer
- Focus Adverse reactions
- Sponsors UroGen Pharma
- 15 Jun 2017 Status changed from active, no longer recruiting to completed.
- 03 Jul 2016 Planned End Date changed from 1 Mar 2018 to 1 Apr 2017.
- 03 Jul 2016 Status changed from recruiting to active, no longer recruiting.